Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Herpes zoster in psoriasis patients treated with tofacitinib

(2017) Kevin L. Winthrop et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

(2017) Philip Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

(2017) Dafna Gladman et al.   NEW ENGLAND JOURNAL OF MEDICINE

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation

(2016) L.C. Coates et al.   BRITISH JOURNAL OF DERMATOLOGY

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study

(2016) James Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study

(2016) Akihiko Asahina et al.   JOURNAL OF DERMATOLOGY

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

(2016) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis

(2016) Steven R. Feldman et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

(2016) C.E.M. Griffiths et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases

(2016) Ana Karina Alves de Medeiros et al.   PLoS One

Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors

(2015) W Gao et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

(2015) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

(2015) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

(2015) Hervé Bachelez et al.   LANCET

JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis

(2014) Ugo Fiocco et al.   IMMUNOLOGIC RESEARCH

Nail Psoriasis, the unknown burden of disease

(2014) K.M.G. Klaassen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2011) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY